登录新浪财经APP 搜索【信披】查看更多考评等级 公司于近日收到横琴鼎典及其一致行动人珠海横琴润汇易出具的《股份减持情况告知函》《股份减持计 划实施完成的告知函》，截至本公告披露日，本次减持计划期限已届满，现将进展情况公告如下： （二）股东本次减持前后持股情况 ■ 二、其他相关说明 证券代码：301130 证券简称：西点药业 公告编号：2025-075 吉林省西点药业科技发展股份有限公司 关于持股5%以上股东及其一致行动人股份减持计划时间届满暨减持结果的公告 持股5%以上股东横琴鼎典股权投资基金合伙企业（有限合伙）及其一致行动人珠海横琴润汇易投资合 伙企业（有限合伙）保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于2025年7月28日披露了《关于持股5%以上 股东及其一致行动人减持股份预披露公告》，持有公司5%以上股份的股东横琴鼎典股权投资基金合伙 企业（有限合伙）（以下简称"横琴鼎典"）及其一致行动人珠海横琴润汇易投资合伙企业（有限合伙） （以下简称 ...

Core Viewpoint - West Point Pharmaceutical (301130) has launched a treatment for mild to moderate Alzheimer's disease, aiming to capitalize on the aging population and enhance the quality of life for the elderly [1] Group 1: Product Development - The oral solution of Rivastigmine tartrate for treating Alzheimer's disease is set to be launched in 2025 [1] Group 2: Strategic Goals - The company adheres to the strategic goal of improving the quality of life for the elderly, emphasizing dignity in their later years [1] - West Point Pharmaceutical has undertaken a series of strategic initiatives to build a product matrix focused on aging-related health [1] Group 3: Market Positioning - The company aims to become a strong competitor in the domestic silver-haired health medication market, leveraging long-term opportunities presented by population aging [1]

证券代码：301130 证券简称：西点药业 公告编号：2025-075 吉林省西点药业科技发展股份有限公司 关于持股 5%以上股东及其一致行动人股份减持计划 时间届满暨减持结果的公告 持股 5%以上股东横琴鼎典股权投资基金合伙企业（有限合伙）及其一致行 动人珠海横琴润汇易投资合伙企业（有限合伙）保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2025 年 7 月 28 日披露了《关于持股 5%以上股东及其一致行动人减持股份预披露公告》， 持有公司 5%以上股份的股东横琴鼎典股权投资基金合伙企业（有限合伙）（以 下简称"横琴鼎典"）及其一致行动人珠海横琴润汇易投资合伙企业（有限合伙） （以下简称"珠海横琴润汇易"）拟于 2025 年 8 月 19 日至 2025 年 11 月 18 日， 以大宗交易、集中竞价交易方式减持公司股份合计不超过 2,294,700 股，即不超 过公司总股本的 3%。其中，在公告披露之日起 15 个交易日后的三个月内采用集 中 ...

格隆汇11月19日丨西点药业(301130.SZ)在投资者互动平台表示，公司现有已上市产品方面，公司拥有 成熟的抗流感药物复方氨酚烷胺胶囊，以及于2025年获得批准上市的抗病毒片临床上用于治疗上呼吸道 感染及流行性感冒。公司的在研项目"瑞香素对人类疾病小鼠模型干预效果的研究"子项目"瑞香素对小 鼠病毒性肺炎模型干预效果研究"中已获得了瑞香素在病毒性肺炎治疗中具有安全性和有效性的实验结 果，已获得《瑞香素在制备治疗病毒性肺炎的药物中的应用》发明专利。 ...

Core Viewpoint - The company has approved the use of idle raised funds and self-owned funds for cash management and entrusted financial management, ensuring the safety of funds and normal project construction [2][4]. Group 1: Cash Management Approval - The company plans to use up to RMB 100 million of idle raised funds and up to RMB 150 million of idle self-owned funds for cash management and entrusted financial management [2]. - The cash management products will be short-term investments with high safety and liquidity, with a maturity not exceeding 12 months [2]. Group 2: Redemption of Cash Management Products - The company has redeemed all principal and earnings from the cash management products as of the announcement date [3]. Group 3: Approval Process - The proposal for cash management was approved by the company's eighth board of directors and the eighth supervisory board meetings [4]. Group 4: Financial Impact - As of the announcement date, the company has a remaining balance of RMB 57 million in idle raised funds for cash management, which is within the authorized limit [9]. - The total remaining balance of self-owned funds used for cash management and entrusted financial management is RMB 114.0084 million, also within the authorized limit [9].

证券代码：301130 证券简称：西点药业 公告编号：2025-074 吉林省西点药业科技发展股份有限公司 关于使用闲置募集资金进行现金管理到期赎回的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2025 年 1 月 20 日召开第八届董事会第十次会议、第八届监事会第十次会议，分别审议通 过了《关于使用部分闲置募集资金进行现金管理及使用部分闲置自有资金进行现 金管理和委托理财的议案》，同意公司在确保募集资金投资项目建设正常进行和 资金安全的前提下，使用额度不超过人民币 1.0 亿元的部分闲置募集资金（含超 募资金）进行现金管理，公司及全资子公司在确保不影响公司日常经营的前提下， 使用额度不超过人民币 1.5 亿元的部分闲置自有资金进行现金管理和委托理财， 用于购买安全性高、流动性好、期限不超过 12 个月的短期投资理财产品。使用 期限自董事会审议通过之日起 12 个月内有效。在上述额度和期限内，资金可循 环滚动使用。具体内容详见公司在巨潮资讯网上披露的《关于使用部分闲置募集 资金进行现金管理及使 ...

Core Viewpoint - Zhonglun New Materials has launched its new energy film project in Xiamen, introducing the "Long Plastic High-Performance Capacitor Film," marking a significant advancement in China's high-end BOPP capacitor film sector [1] Company Summary - Zhonglun New Materials is recognized as a national manufacturing champion, expanding into the high-end BOPP capacitor film market with leading global technology [1] - The company is the only domestic entity capable of stable mass production of BOPP capacitor films with "large width, step line, and ultra-thin thickness below 3 microns" [1] - The newly launched production line features a 6.4-meter wide production line utilizing an innovative biaxial stretching process [1] Industry Summary - The "Long Plastic High-Performance Capacitor Film" is the only product in the industry that offers "zero joints, high performance, and zero defects," catering to the needs of the new energy vehicle and photovoltaic sectors [1] - This project, with a total investment of 2.5 billion yuan and covering an area of 134,400 square meters, aims to fill the domestic capacity gap in high-end capacitor films [1] - The initiative supports China's goal of reducing reliance on imports of high-end capacitor films, transitioning Zhonglun from the largest global BOPA film supplier to a comprehensive champion covering various high-performance film materials [1]

证券代码：301130 证券简称：西点药业 公告编号：2025-073 吉林省西点药业科技发展股份有限公司 三、审批程序 关于使用闲置募集资金及自有资金进行现金管理和委托理财 到期赎回并继续使用闲置募集资金进行现金管理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2025 年 1 月 20 日召开第八届董事会第十次会议、第八届监事会第十次会议，分别审议通 过了《关于使用部分闲置募集资金进行现金管理及使用部分闲置自有资金进行现 金管理和委托理财的议案》，同意公司在确保募集资金投资项目建设正常进行和 资金安全的前提下，使用额度不超过人民币 1.0 亿元的部分闲置募集资金（含超 募资金）进行现金管理，公司及全资子公司在确保不影响公司日常经营的前提下， 使用额度不超过人民币 1.5 亿元的部分闲置自有资金进行现金管理和委托理财， 用于购买安全性高、流动性好、期限不超过 12 个月的短期投资理财产品。使用 期限自董事会审议通过之日起 12 个月内有效。在上述额度和期限内，资金可循 环滚动使用。具体内容详 ...

Core Viewpoint - The announcement details the progress of share reduction by major shareholders of Jilin Xidian Pharmaceutical Technology Development Co., Ltd., indicating that the reduction will not affect the company's control structure or governance [3][5][20]. Summary by Sections Shareholder Reduction Details - The main entities involved in the share reduction are Hengqin Dingdian Equity Investment Fund Partnership (Limited Partnership) and its concerted actor Zhuhai Hengqin Runhuiyi Investment Partnership (Limited Partnership), who hold over 5% of the shares [3][4]. - The total shares to be reduced amount to a maximum of 2,294,700 shares, which is not more than 3% of the company's total share capital [4]. - As of November 3, 2025, a total of 765,019 shares have been reduced, representing 1.0001% of the total share capital [4][5]. Shareholding Structure - After the reduction, Hengqin Dingdian and Zhuhai Hengqin Runhuiyi collectively hold 7,649,396 shares, which is 9.9999% of the total share capital, still qualifying them as major shareholders [3][5]. - The shareholding percentage decreased from 11.0000% to 9.9999% following the reduction [5]. Impact on Company Governance - The reduction will not lead to any changes in the company's controlling shareholder or actual controller, nor will it significantly impact the company's governance structure or ongoing operations [3][20]. - The reduction process is compliant with pre-disclosure regulations and does not trigger a mandatory tender offer [7][8]. Future Plans - The shareholders may continue to reduce their holdings within the next 12 months, depending on their financial needs [16].

Core Viewpoint - West Point Pharmaceutical (301130.SZ) announced a share reduction plan involving the sale of 765,019 shares, representing 1.0001% of the company's total equity, by Hengqin Dingdian and its concerted action party, Zhuhai Hengqin Runhuiyi, through centralized bidding or block trading from October 27, 2025, to November 3, 2025 [1] Summary by Category - **Share Reduction Details** - The share reduction involves a total of 765,019 shares [1] - This amount constitutes 1.0001% of the company's total share capital [1] - The reduction plan is not yet fully executed [1]